این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Middle East Journal of Cancer، جلد ۱۳، شماره ۲، صفحات ۲۴۷-۲۵۴
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Prognostic Significance of PD-L1 and PTEN Expression in Prostatic Cancer
چکیده انگلیسی مقاله Background: Programmed death- ligand 1(PD-L1) acts as an immune checkpoint inhibitor. Phosphatase and tensin homolog (PTEN) is a somatically mutated tumor suppressor gene in numerous types of human cancer. The current study aimed to assess the prognostic value of PD-L1 and PTEN expression in prostatic cancer patients, as well as their relationship with the clinicopathological features of the disease. Method: A total of 55 needle biopsy specimens were retrospectively diagnosed as prostatic adenocarcinoma. Immunohistochemical staining with PD-L1 and PTEN were evaluated in all the cases. The patients were followed up for 5 years in order to detect disease recurrence and survival. Results: PD-L1 expression in Prostate cancer was positively correlated with high prostatic specific antigen (PSA), higher Gleason score, advanced stage, higher tumor relapse, and worse disease-free and overall survival (P < 0.001). PTEN loss was significantly associated with high PSA, higher Gleason score < 7, advanced tumor stage, tumor relapse, and worse disease-free and overall survival (P < 0.001). We observed a significant negative correlation between PTEN and PD-L1. Conclusion: PDL-1 and PTEN are prognostic markers for prostate cancer, which can differentiate between the patients who are at a high risk of disease progression and may successively provide novel targeted therapies.
کلیدواژه‌های انگلیسی مقاله Prostatic Neoplasms, PD-L1, PTEN, Immunohistochemistry, Prognosis
نویسندگان مقاله Noha F. Elaidy |
Department of Pathology, School of Medicine, Zagazig University, Zagazig, Egypt

Eman H. Abdelbary |
Department of Pathology, School of Medicine, Zagazig University, Zagazig, Egypt

Mohamed W. Hegazy |
Department of Clinical Oncology and Nuclear Medicine, School of Medicine, Zagazig University, Zagazig, Egypt

Amira Elwan |
Department of Clinical Oncology and Nuclear Medicine, School of Medicine, Zagazig University, Zagazig, Egypt

نشانی اینترنتی https://mejc.sums.ac.ir/article_47966_41bcec07df93256d95e63960382f1498.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات